文献速递眼底病与葡萄膜炎

成纤维细胞生长因子受体抑制剂相关视网膜病变的临床与形态学特征

Clinical and Morphologic Characteristics of Fibroblast Growth Factor Receptor Inhibitor-Associated Retinopathy.
PubMed 文献 · JAMA Ophthalmol · 2021-01-01

这项回顾性病例系列纳入单中心146例接受FGFR抑制剂抗癌治疗的患者,其中20例(13.7%)出现视网膜病变,表现为视网膜下液灶,类似其他MAPK通路抑制剂。视网膜下液多在用药后中位21天检出,多数无需干预或停药即可自行消退,未导致不可逆视力丧失。

要点

  • 146例接受FGFR抑制剂治疗者中20例(13.7%)出现视网膜病变,共40眼。
  • 用药至首次检出视网膜下液的中位时间为21天(范围5-125天)。
  • 有随访的26眼中,除1例患者外视网膜下液均无需医疗干预或停药而消退。

核心结论

  • FGFR抑制剂可导致类似其他MAPK通路抑制剂的视网膜下液灶,本系列中未造成不可逆视力丧失,病变自限且无需医疗干预。

研究设计与样本

  • 回顾性病例系列,纳入2012年3月至2021年1月单中心接受FGFR抑制剂抗癌治疗的146例患者,其中20例经OCT确认视网膜病变,共40眼,其余患者OCT判为正常。

主要发现

  • 146例中20例(13.7%)出现FGFR抑制剂相关视网膜病变,20例中11例(55%)为女性,中位年龄62.6岁(范围42.7-86.0)。
  • 用药至首次检出视网膜下液的中位时间为21天(范围5-125天,均值32天)。
  • 基线中位logMAR最佳矫正视力为0(四分位距0-0.1);积液时11眼视力下降,该亚组基线中位BCVA为0(0-0.1),从基线到积液的中位BCVA变化为-0.1(-0.2至-0.1)。
  • 有随访的26眼(65%)中,除1例患者外视网膜下液均无需医疗干预或中断用药而消退;消退时中位BCVA为0.1(0-0.1),从基线到消退的中位BCVA变化为0(-0.03至0)。
  • 无患者因视网膜病变停止药物治疗。

临床怎么用

  • 接受FGFR抑制剂治疗的患者出现视觉症状时,应考虑药物相关视网膜下液的可能,OCT有助于识别。
  • 本系列中该视网膜病变多为自限性,无需医疗干预或停药即可消退。

局限性

  • 为回顾性研究,无法确切确定该不良反应的精确发生率或严重程度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Fibroblast growth factor receptor (FGFR) 1 to 4 inhibitors are approved by the US Food and Drug Administration and suppress the mitogen-activated protein kinase (MAPK) pathway, with a potential for treatment-related retinopathy. To date, implications of FGFR inhibitor-associated ocular toxic effects are poorly described. Therefore, more detailed clinical descriptions of this ocular toxic effect could help explain visual symptoms while receiving drug therapy. OBJECTIVE: To describe the clinical and morphologic characteristics of serous retinal disturbances associated with FGFR inhibitors. DESIGN, SETTING, AND PARTICIPANTS: In this retrospective case series, 146 patients receiving FGFR inhibitors as cancer treatment at a single tertiary referral center were included. This study included 40 eyes of 20 patients with retinopathy by optical coherence tomography (OCT). OCTs were obtained on the remaining patients and the results were judged normal. Patients were recruited from March 2012 to January 2021. MAIN OUTCOMES AND MEASURES: Characteristics of treatment-emergent choroidal and retinal OCT abnormalities as compared with baseline OCT, associated with visual acuity at presentation and at fluid resolution. RESULTS: A total of 20 of 146 patients (13.7%) exhibited FGFR inhibitor-associated retinopathy. Of these 20 patients, 11 (55%) were female, and the median (range) age was 62.6 (42.7-86.0) years. The median (range; mean) time from medication start to initial subretinal fluid detection was 21 (5-125; 32) days. The median (interquartile range [IQR]) baseline logMAR best-corrected visual acuity (BCVA) was 0 (0-0.1). At fluid accumulation, 11 eyes had decreased vision: the median (IQR) subgroup baseline BCVA was 0 (0-0.1); and the median (IQR) BCVA change from baseline to accumulation was -0.1 (-0.2 to -0.1). For 26 eyes (65%) with follow-up, the subretinal fluid resolved without medical intervention or drug interruption in all but 1 patient. At fluid resolution, the median (IQR) BCVA was 0.1 (0-0.1), and the change in median (IQR) BCVA from baseline to fluid resolution was 0 (-0.03 to 0). No patient discontinued drug therapy on account of their retinopathy. CONCLUSIONS AND RELEVANCE: FGFR inhibitors result in subretinal fluid foci similar to other drugs that inhibit the MAPK pathway. In this series, FGFR inhibitors did not cause irreversible loss of vision; the retinopathy was self-limited and did not require medical intervention. These results may explain visual symptoms while taking the drug, although the precise frequency or magnitude of this adverse effect cannot be determined with certainty from this retrospective investigation.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Francis JH, Harding JJ, Schram AM, et al. Clinical and Morphologic Characteristics of Fibroblast Growth Factor Receptor Inhibitor-Associated Retinopathy. JAMA Ophthalmol. 2021. PMID: 34473206. doi:10.1001/jamaophthalmol.2021.3331

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。